The members of the Southwest Oncology Group have treated thirteen patients with Hodgkin's disease and thirty-seven with non-Hodgkin's lymphoma with mitoxantrone on the every three week schedule. While the result (\313 responses in Hodgkin's; \937 responses in non-Hodgkin's lymphoma) is not striking, there is a definite antitumor activity in a very heavily pretreated group of patients. Toxicity was acceptable. Additional trials in lymphoma are planned using mitoxantrone in combination with BCNU.
|Idioma original||English (US)|
|Número de páginas||6|
|Publicación||Investigational New Drugs|
|Estado||Published - mar 1983|
|Publicado de forma externa||Sí|
ASJC Scopus subject areas
- Pharmacology (medical)